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Abstract: The present study reports two cases of large ovarian malignancy during pregnancy, 
which is very rare. The two patients were received between Nov 2012 and Feb 2013 at Gyneco-
logical and Obstetrical Department, Women’s Hospital, School of Medicine, Zhejiang University 
(People’s Republic of China). Both cases present tumor sized more than 20 cm, with one case 
of 40 cm. Both patients underwent timely cesarean section, with survival of the Child, and 
successful removal of the tumor. All patients showed good outcome in the follow-up period. 
Therefore the large ovarian malignancy during pregnancy could be well treated after careful 
clinical evaluation.
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Introduction
Ovarian malignancies during pregnancy are rare.1–7 In a large survey in Canada, the inci-
dence of malignant ovarian tumors during pregnancy was 0.0416 per 1,000   pregnancies, 
comprising mainly borderline tumors followed by epithelial tumors.4,8 In Europe and 
the USA, the incidence was 0.04–0.11 per 1,000 pregnancies, and comprised mostly 
borderline tumors.4 In Asia, the incidence was 0.106 per 1,000 pregnancies, with 
40% being borderline tumors.3 It was also found that grade I tumors accounted for 
up to 62.5% of all cases, and histological type was mainly low-grade malignancy 
(62.5%). Borderline tumors accounted for up to 50% of these cases.4,5,8–10 Previously 
reported cases have had tumor diameters in the range of 5–24 cm. Here we present 
two rare cases of large ovarian malignancy during pregnancy, both involving tumors 
with diameters larger than 20 cm, with one reaching 40 cm.
Case report 1
Our first case was a 24-year-old married woman who was admitted to our hospital on 
February 4, 2013, due to 35 weeks of menopause, and detection of pelvic mass for 
4 months. The first ultrasound examination on September 25, 2012 indicated an intra-
uterine pregnancy with a single live embryo and a large 20–30 cm abdominal cystic 
mass. A second ultrasound examination on November 7, 2012 showed the mass to be 
more than 30 cm in diameter. The patient reported no specific symptoms and was not 
receiving any medication.
On admission to our hospital, general examination revealed a body temperature 
of 37.4°C, a heart rate of 105 beats per minute, a respiratory rate of 22 per minute, 
a blood pressure of 140/100 mmHg, and a bulging belly shape. Her fundal height 
was 52 cm and her abdominal circumference was 120 cm. The patient had occasional OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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contractions, but vaginal examination showed that the cervix 
was not open. Ultrasound examination on February 4, 2013 
showed the fetus to be in the left occiput anterior position, 
a fetal heart rate of 124 beats per minute, fetal movement, 
a femur length of 6.1 cm, an anterior placenta grade I +, an 
amniotic fluid level of 3 cm, and an umbilical artery S/D 
ratio of 3.0. The abdominal cavity was filled with plenty of 
fluid, measuring 25.4 cm at its deepest point. A substantial 
11.2×11.6×10.4 cm cauliflower-shaped mass was detectable, 
with little blood flow in the vein blood flow. A 5.6×4.5×5.6 
cm cystic mass was present to the right of the uterus, show-
ing separation inside and clean solution inside. Urinalysis 
revealed proteinuria ++ and blood investigations revealed 
total protein 53.7 g/L, albumin 27.1 g/L, C-reactive protein 
31.2 mg/L, aspartate aminotransferase 84 U/L,   alanine ami-
notransferase 43 U/L, and tumor markers (cancer antigen 1.1 
ng/mL, alpha-fetoprotein 168.8 ng/mL, CA-125 50.9 U/mL), 
with no other obvious abnormalities.
The patient was diagnosed as being at 35 weeks’ gesta-
tion with a left occiput anterior pregnancy, possible fetal 
distress, severe pre-eclampsia, and an abdominal mass to be 
determined (query ovarian tumor). The patient was started 
on oral labetalol 100 mg at 12-hour intervals to decrease 
her blood pressure, intravenous magnesium sulfate 40 mL 
as an antispasmodic, 100 mL of intravenous albumin as a 
protein supplement, and a 40 mL injection of compound 
glycyrrhizin for liver protection. After consultation with 
doctors from the departments of medicine and oncology, 
and obtaining approval from the department of critical care, 
the patient underwent lower uterine segment cesarean sec-
tion, laparotomy, and fertility-preserving ovarian cancer 
resection (right adnexectomy, greater omentum resection, 
pelvic lymph node dissection, appendectomy, left ovary 
necropsy) under epidural anesthesia. During surgery, 50 mL 
of free, clear-colored, pelvic fluid was taken for cytology 
examination.
The uterus was in the anterior position, with a size 
indicating 8 months’ gestation. A lower uterine segment 
cesarean section was performed successfully, with head 
position delivery of a live female baby weighing 2,750 g 
with an Apgar score of 9 at one and 5 minutes. The uterine 
wall showed abnormal contraction, which resolved following 
hemabate injection. After the surgery, we found that the uter-
ine surface was smooth, with a rectal fossa uterus and bladder 
peritoneal fold back membrane, and a normal left ovary with 
a smooth surface showing no adhesion to surrounding tissues. 
The left fallopian tube showed no abnormalities, with free 
end   visible. The right ovary was cystic and was increased 
in size to 45×40×40 cm, with the top edge reaching the 
diaphragm and adhering to the greater omentum. The cystic 
wall was thick and unbroken. The right fallopian tube was 
thickened, and free end could be seen. The diaphragmatic 
surface was smooth, and the pelvic lymph nodes showed no 
abnormalities.
Right oophorectomy was then attempted; however, during 
surgery, the right ovarian tumor was found to be too large 
to expose and remove directly. Aspiration of cystic fluid 
revealed the polycystic nature of the tumor. During aspira-
tion, the cyst ruptured, releasing about 15,000 mL of pale 
yellow, clear, and viscous, cystic fluid. The right accessory 
ovary was then removed, exposing a 45×40×40 cm mass 
with a smooth surface and polycystic features, and a solid 
12×11×10 cm mass. Intraoperative frozen section examina-
tion revealed a local ovarian mucinous cystadenoma at the 
right side of the borderline. Examination of the pelvic fluid 
revealed red blood cells and inflammatory cells, but no tumor 
cells.   Intraoperative discussion with the patient and family 
members lead to fertility-sparing radical surgery for ovarian 
Figure 1 Huge ovarian tumor during pregnancy.
Notes: (A) General view of the ovarian tumor in case one (after removal of 10,000 mL of cyst fluid) during surgery. The full size of the tumor was 45×40×40 cm. (B) internal side 
of the cyst after opening the ovarian tumor in case two (smooth surface, multiple-room cyst. Pathological examination showed a juvenile granulosa cell tumor.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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cancer. The surgery proceeded successfully, with blood loss 
of 500 mL, a steady pulse, and a clear-colored urine output 
of around 1,000 mL. After surgery, pathological analysis 
confirmed a diagnosis of right grade I borderline mucinous 
ovarian adenocarcinoma. The right fallopian tube tissue and 
blood vessels were negative. Ten surrounding lymph nodes 
were also negative.
Immunohistochemistry revealed CK-negative and 
Vimentin-positive staining. Nine days after surgery, the 
patient was discharged from hospital with a recommenda-
tion for chemotherapy. The patient was in a stable condition 
(without chemotherapy) at follow-up 3 months after surgery 
(Figure 1).
Case report 2
Our second case was a 24-year-old married woman who 
was admitted to our hospital on November 7, 2012 due to 
32 weeks of menopause, and 2 days after detection of pelvic 
mass. Examination at 16 weeks had shown no abnormality 
and indicated a low-risk pregnancy. On November 5, 2012, 
at 32 weeks’ gestation, ultrasound examination revealed a 
“right upper abdominal split septum-like huge cystic mass 
(right ovarian cyst?)”. On admission to hospital, ultrasound 
examination revealed little amniotic fluid, a cystic mass in 
the right cavity, which was suspicious for ovarian cancer. The 
patient had gained 18 kg in weight during her pregnancy. 
Physical examination revealed a body temperature of 36.6°C, 
a heart rate of 96 beats per minute, a respiratory rate of 18 
per minute, blood pressure 109/83 mmHg, no tenderness or 
rebound tenderness, and a large palpable mass in the right 
upper quadrant. The height of the uterus was 29 cm and the 
abdominal circumference was 96 cm, with no contraction. 
The fetus was in the left occiput anterior position, the fetal 
heart rate was 158 beats per minute, fetal movement was 
detectable, femur length was 6.0 cm, Gr-level anterior pla-
centa, the amniotic fluid index was 7.4 cm, and the umbilical 
artery S/D ratio was 2.7. The huge cystic mass was in the right 
cavity, with top edge to the liver and bottom edge to the pelvis, 
the size of 28×25×12 cm; it shows multiple rooms separated 
and rich blood flow, the cyst fluids are not in clear color. 
One room shows uneven echo and rich blood flow, RI: 0.2. 
There was some free fluid in the right lower quadrant, with 
a depth of 6.1 cm. Examination of tumor markers revealed a 
carcinoembryonic antigen of 0.4 ng/mL, an alfa-fetoprotein 
of 266.8 ng/mL, and a CA-125 of 466.9 U/mL.
On November 13, 2012, the patient underwent lower 
uterine segment cesarean section and fertility-preserving 
ovarian cancer resection (right adnexectomy, partial greater 
omentum resection, pelvic lymph node dissection, pelvic 
lymphadenectomy, peritoneal multiple biopsy) under 
epidural anesthesia. During surgery, 200 mL of clear-
colored free pelvic liquid was taken and used for cytology 
examination.
A lower uterine segment cesarean section was per-
formed successfully, with safe delivery of a live female 
baby   weighing 1,800 g with an Apgar score of 10 at one 
and 5 minutes. The left ovary was of normal size, while the 
right ovary showed cystic enlargement to 30×25×15 cm. 
The top edge of the right ovary reached to the diaphragm, 
the right reached to the colon, and the left extended to the 
greater curvature of the stomach. It had a smooth surface 
and there was no adhesion to surrounding tissues or rupture. 
The right fallopian tube was edematous and thickened, and 
free end could be seen. There were no clear abnormalities 
in the stomach, liver, or spleen, and the pelvic lymph nodes 
were normal. Aspiration of 2,000 mL of cystic fluid result 
in the exposure of the right accessory tumor, dissection of 
which showed a cystic mass of 30×25×15 cm with a smooth 
surface. Examination of pelvic fluid revealed no cancer cells. 
Rapid frozen section examination suggested a right ovarian 
juvenile granulosa cell tumor.
Routine pathological examination after surgery con-
firmed the right ovarian juvenile granulosa cell tumor. 
The right fallopian tube and blood vessels were negative, 
and 19   surrounding lymph nodes were also negative. On 
the first day after surgery, hematology revealed white 
cells 16.5×109/L, neutrophils 66.4%, and hemoglobin 
94 g/L, and biochemistry showed total protein 45.2 g/L, 
albumin 26.4 g/L, C-reactive protein 94.6 mg/L, and 
plasma D-2 dimer 4.16 mg/L. The patient was treated with 
anti-inflammatory drugs and symptomatic support. Six days 
after surgery, blood investigations revealed white blood 
cells of 8.0×109/L, neutrophils 65.9%, hemoglobin 107 g/L,   
C-reactive protein 27.3 mg/L, and plasma D-2 dimer   
2.97 mg/L, along with tumor markers (alfa-fetoprotein 
39.5 ng/mL, CA-125 359.9 U/mL, CA-153 32.6 U/mL). 
Eight days after surgery, the patient was transferred to the 
department of oncology. Starting on November 23, 2012, the 
patient received first-line BEP (bleomycin, etoposide, 
diamminedichloroplatinum(II) chemotherapy) as recom-
mended by the International Federation of Gynecology and 
Obstetrics for cord stromal tumors, as well as euprolide 
by hypodermic injection to preserve ovarian function. The 
second phase started on December 25, 2012, and the third 
phase on January 23, 2013.   Follow-up after 2 years showed 
that they maintained the healthy state.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Discussion
Previous reports indicate that most accessory ovarian masses 
are benign, and that malignant ovary tumors are rare during 
pregnancy. However, at our hospital, we have diagnosed two 
cases in the past 2 years (2012–2013).
Patients may have no symptoms and no evidence to sug-
gest that the tumor is affecting fetal growth and development. 
The large size of the tumor may at some time point hinder 
uterus growth, leading to premature birth or miscarriage. 
Clinical diagnosis of ovarian tumors at an early stage relies on 
bimanual, triple diagnosis, or sonographic findings, although 
when tumor growth is rapid, it may cause bloating, abdominal 
pain, an abdominal mass, and marked pressure symptoms. 
When the tumor ruptures due to external pressure, there might 
be internal bleeding and symptoms of peritoneal irritation.
Pelvic ultrasound examination is the most reliable method 
for detection of an ovarian tumor, in terms of position, size, 
morphology, relationship to the uterus, with cystic fluid or 
not, with cyst wall separation or not and existence of pelvic 
fluid. Once a pelvic mass is detected, ultrasound follow-up 
during pregnancy helps to determine the nature of the mass. 
The mass should be observed dynamically under ultrasound 
  examination. The vast majority of ovarian cysts are follicular 
cysts or corpus luteum cysts, with a diameter of less than 5 cm 
(very rarely reaching 11 cm). Ninety percent of functional 
cysts disappear as the pregnancy progresses, and diminishes 
at 14 weeks. Six percent of cysts are less than 6 cm, and 39% 
larger than 6 cm persist afterwards. A single cyst measuring 
less than 10 cm, one side, and without ascites can be left to 
18 weeks without further medication; however, if the cyst 
persistently increases in size, surgical exploration is required. 
For mixed cysts larger than 5 cm, bilateral sides, or with 
nipple should be followed up with ultrasound; if it persists 
or the size increases by 30%–50%, surgical exploration is 
required.2,11,12 It has been reported that cysts larger than 15 cm 
are 12 times more likely to be malignant than cysts less than 
6 cm in diameter.13 In the first case presented in this report, 
ultrasound revealed a solid mass larger than 10 cm, and blood 
flow suggested a malignant tumor. It should be noted that 
the ultrasound diagnosis is limited by the experience of the 
clinicians and sonographers, and is blocked by abdominal 
organs during pregnancy, which could lead to   misdiagnosis. 
For instance, cyst fluid could have been considered to be 
pelvic fluid on early ultrasound examination in the first case. 
Therefore, routine gynecological ultrasound examination 
should be performed to exclude any possible mass, and be 
followed by magnetic resonance imaging in cases where there 
is diagnostic difficulty.
CA-125 is a widely used epithelial ovarian tumor marker, 
with an 80% positive detection rate in most ovarian serous 
  adenocarcinomas. However, CA-125 is not specific for ovar-
ian tumors, and its levels also increase during pregnancy. 
Nonpregnant patients with nonserous, mixed, or mucinous 
borderline ovarian tumors have been found to have CA-125 
levels of 9,918 kU/L, 11,718 kU/L, and 3,419 kU/L, 
respectively.14,15 In our two patients, increased CA-125 may 
have been of some diagnostic value, but CA-125 still lacks 
enough accuracy in evaluating the treatment efficiency.12
Treatment of a malignant ovarian tumor during pregnancy 
is not significantly different from that in nonpregnant women. 
The diagnosis should be followed by timely surgery, irre-
spective of the stage of pregnancy. An intraoperative frozen 
section is required to identify the tumor. For a malignant 
ovarian tumor during early pregnancy, abortion is required 
as the standard for following managements.
There are several features characteristic of malignant 
ovarian tumors during pregnancy: they tend to occur mainly 
in first-baby young mothers; tumors are mostly in an early 
phase; cell differentiation is mainly low-grade malignant; 
and the prognosis is better than in nonpregnant cases. 
Therefore, some patients can be treated with conservative 
surgery: Stage Ia period of granulosa cell tumors, Stage Ia 
dysgerminoma, Stage Ia1 grade immature teratoma, Stage Ia 
borderline epithelial tumors, Stage Ia1 grade squamous cell 
carcinoma. For unilateral tumor cases, the accessory tumor 
can be removed and a biopsy should be performed for cyto-
logical examination. If no cancer cells are found, there is 
no need for chemotherapy and the pregnancy can continue. 
After the delivery, a second surgery is required. If there are 
clear symptoms of ovarian cancer, such as abdominal disten-
sion, rapid cyst growth, signs of nipples or blood flow in the 
cyst, or presence of ascites, surgery should be performed 
immediately regardless of the pregnancy. If the mother has 
a strong desire for the fetus to survive, conservative surgery 
can be performed and the second surgery can be performed 
after cesarean section. If the tumor grade increases, adjuvant 
chemotherapy or radical surgery may be required.16 For a 
progressive tumor, the pregnancy should be terminated before 
cytoreductive surgery.
For epithelial cancer, combined platinum-based che-
motherapy can be used. For nonepithelial cancer, the BEP, 
etoposide-cisplatin, and cisplatin-vinblastine-bleomycin 
chemotherapy protocol shows no adverse effects on the fetus. 
After termination of pregnancy, combined platinum-paclitaxel 
therapy can be used. Intraperitoneal chemotherapy is effective 
after cytoreductive surgery for Phase III ovarian tumors.17OncoTargets and Therapy
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In summary, the treatment of a malignant ovarian tumor 
during pregnancy should be based on stage of pregnancy, the 
nature of the tumor, individual symptoms, safety of the fetus, 
and considering the fertility of the patient after   treatment. 
Treatment should be given to maximize the survival rate and 
at the most proper time point.
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